PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Part of paid clinical trials in Duarte, California.

Sponsor
CytomX Therapeutics
Study ID
NCT03993379
Phase
PHASE2
Status
Terminated

Conditions

  • Solid Tumor
  • Unresectable or Metastatic Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CX-072 — DRUG
    CX-072 in combination with ipilimumab
  • Ipilimumab — DRUG
    CX-072 in combination with ipilimumab

Study Details

To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)

Key Dates

Start date
Nov 20, 2019
Status verified
Dec 2025
Primary completion
May 21, 2020
Completion
May 21, 2020

Study Design

Enrollment
3 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: CX-072 in combination with anti-cancer therapy-front line
    histologically or cytologically confirmed solid tumor who have received no prior treatment
  • Experimental: CX-072 in combination with ipilimumab
    histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma who have experienced progressive disease or relapse following treatment with a PD-1/PD-L1 immune checkpoint inhibitor
  • Experimental: CX-072 in combination with anti-cancer therapy-Progressed
    histologically or cytologically confirmed, advanced/unresectable or metastatic solid tumor that have experienced disease progression during or following treatment with platinum based therapy
  • Experimental: CX-072 in combination with anti-cancer therapy-Neoadjuvant
    neo-adjuvant study in subjects with histologically confirmed solid tumor

Primary Outcome Measure

Overall Response Rate by RECIST v 1.1 [ Time Frame: 1 year ]

Locations (14)

FacilityCityStateZIPSite coordinators
City of Hope National Medical CenterDuarteCalifornia91010-
The Angeles Clinic and Research InstituteLos AngelesCalifornia90025-
Beacon Cancer CareCoeur d'AleneIdaho83814-
University of ChicagoChicagoIllinois60637-
Norton Cancer InstituteLouisvilleKentucky40202-
Dana Farber Cancer InstituteBostonMassachusetts02215-
Columbia Medical CenterNew YorkNew York10032-
NYC Cancer InstituteNew YorkNew York10016-
Oregon Health & Science CenterPortlandOregon97210-
Providence Portland Medical CenterPortlandOregon97213-
UPMC Hillman Cancer CenterPittsburghPennsylvania15232-
Inova Dwight and March Schar Cancer InstituteFairfaxVirginia22031-
Virginia Cancer SpecialistsFairfaxVirginia22031-
Multicare Institute for Research and InnovationSpokaneWashington99204-

Find similar trials in Duarte, CA

By research site
City of Hope National Medical Center· Duarte, CAThe Angeles Clinic and Research Institute· Los Angeles, CABeacon Cancer Care· Coeur d'Alene, IDUniversity of Chicago· Chicago, ILNorton Cancer Institute· Louisville, KYDana Farber Cancer Institute· Boston, MA

Related Studies